Drug Trial Radar · NCT01914419
Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage
Last checked: Nov 19, 2026Latest source record: Mar 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,983
Actual
Start
Apr 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Gynuity Health ProjectsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- El Galaa Teaching Hospital; University of Alexandria
- First posted
- Aug 2, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will evaluate whether prophylactic oxytocin administered in the third stage of labor via intravenous (IV) infusion or IV bolus reduces the rate of postpartum hemorrhage compared to intramuscular (IM) injection.
Conditions
- Postpartum Hemorrhage
Interventions
OxytocinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of women with postpartum blood loss equal to or greater than 500 mLTime frame: 1 hour after delivery of baby
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shatby Maternity Hospital, Alexandria University
Alexandria, Egypt
El Galaa Teaching Hospital
Cairo, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.